Physicists at MIT have introduced a technique to study the interior of an atom’s nucleus by relying on the atom’s own electrons as “messengers” inside a molecule.
In research published on October 23 in Science, the team precisely measured the…
Blog
-
The math says life shouldn’t exist, but somehow it does
A groundbreaking study is taking a fresh look at one of science’s oldest questions: how did life arise from nonliving material on early Earth? Researcher Robert G. Endres of Imperial College London has created a new mathematical framework…
Continue Reading
-
Novartis Avidity Biosciences in talks
Signage for Novartis AG at a building in the company’s headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023.
Bloomberg | Bloomberg | Getty Images
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported, citing a person familiar with the matter.
A deal could be announced as early as Sunday, the report said.
Novartis and Avidity didn’t immediately respond to CNBC’s requests for comment.
Avidity specializes in developing an innovative class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates. RNA-based therapeutics are a relatively new class of medications that work by altering how genes are expressed to treat or prevent diseases.
The reported discussions come as Novartis ramps up its research and development division. The company earlier this year pledged to invest $23 billion to build out its U.S.-based infrastructure, which includes plans to construct a second R&D hub in San Diego.
The company has also struck two key deals with Anthos Therapeutics and Regulus Therapeutics this year to boost its development and manufacturing of cardiovascular and kidney disease drugs.
Avidity shares closed at $49.15 on Friday. The stock, which has a market capitalization of roughly $7.2 billion, is up nearly 70% since the beginning of the year. Novartis shares closed at $130.36 on Friday.
Read the complete Bloomberg News report here.
Continue Reading
-
Radiohead’s Thom Yorke says he won’t play Israel under Netanyahu, but slams BDS movement
Radiohead frontman Thom Yorke told the UK’s Sunday Times that he won’t play in Israel again while Prime Minister Benjamin Netanyahu is in power, and that Israel should not be part of Eurovision, while also criticizing pro-Palestinian…
Continue Reading
-
Fonseca's rise continues, wins biggest career title in Basel – ATP Tour
- Fonseca’s rise continues, wins biggest career title in Basel ATP Tour
- Joao Fonseca vs Jaume Munar Preview: Head-to-Head and Prediction for Swiss Indoors Basel 2025 PFSN
- Tennis, ATP – Swiss Indoors 2025: Davidovich Fokina takes out Humbert
Continue Reading
-
Wan 2.5 vs. Wan 2.2: Inside the Next Leap of AI Video Generation on WanVideo.co
The rapid evolution of AI video generation has reshaped how creators, educators, and marketers produce visual content. In this fast-moving landscape, models like Wan 2.2 laid the foundation for prompt-based video creation —…
Continue Reading
-
Radiohead’s Thom Yorke says would not now play in Israel
Radiohead frontman Thom Yorke has said in a British newspaper interview he would not now perform in Israel, eight years after the band defied pro-Palestinian activists to play a Tel Aviv gig.
“Absolutely not. I wouldn’t want to be 5,000 miles…
Continue Reading
-
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
Cytokines are believed to play a key role in treatment resistance in patients with
ovarian cancer , according to a new review article published in theInternational Journal of Cancer , but the exact role and mechanisms behind it have remained…Continue Reading
-
See Lana Del Rey Cover Neil Young’s ‘The Needle and the Damage Done’
“I thought we’d get started with a little bit of Neil,” singer says before playing Harvest classic at charity show
Lana Del Rey took the stage Saturday at Neil Young’s “Harvest Moon” charity concert, with the singer…
Continue Reading
